NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

NEW YORK  , July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investo

NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

NEW YORK, July 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

HC Wainwright & Co. analyst Raghuram Selvaraju assumes Larimar Therapeutics (NASDAQ:LRMR) wit

NEW YORK, July 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

Baird analyst Joel Beatty maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lowe

Larimar Therapeutics, Inc. (LRMR) Discusses Regulatory Progress and Long-Term Data for Nomlabofusp i

Larimar Therapeutics Inc (LRMR) submits first module of Biologics License Application for investigat

US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrol

Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 159.6% to $7.68 during Monday&

Universe Pharmaceuticals Inc (NASDAQ: UPC) surged 228.4% to $9.72 in pre-market trading after announ

FDA alignment on submission of BLA data package in multi-disciplinary Type B pre-BLA meeting minutes

BALA CYNWYD, Pa., June 29, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LR

BALA CYNWYD, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LR

JP Morgan analyst Tessa Romero initiates coverage on Larimar Therapeutics (NASDAQ:LRMR) with a Ov

Top analysts changed outlook on top names. Keybanc, Leerink, Wedbush, DA Davidson, Benchmark, Piper

Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lo

Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.31) per share which beat the ana

Intending to initiate rolling BLA seeking accelerated approval with submission of nonclinical and cl

BALA CYNWYD, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: L

Shares of Larimar Therapeutics, Inc. (NASDAQ: LRMR - Get Free Report) have been assigned a consensus

Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and ra

Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.73) per share which missed the a

* Pro forma cash, cash equivalents, and marketable securities of $244.5 million reflects $136.9 mill

Larimar Therapeutics, Inc. (NASDAQ: LRMR - Get Free Report) was the target of some unusual options t

Tom Yeung here with your Sunday Digest .  In 2015, I visited the observatory at One World Trade Cent

Larimar's stock jumps 55% in a month after the FDA grants breakthrough therapy status to its FA drug

BALA CYNWYD, Pa., March 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: L

Guru Stock PicksKen Fisher has made the following transactions:Reduce in DEO by 23.8%Sold out in VSH

Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and ra

Larimar Therapeutics, Inc. ("Larimar") (Nasdaq: LRMR), a clinical-stage biotechnology compan

Larimar Therapeutics Inc (NASDAQ:LRMR) shares are soaring on Wednesday after multiple analysts reite

Citigroup analyst Samantha Semenkow maintains Larimar Therapeutics (NASDAQ:LRMR) with a Buy and r

Wedbush analyst Laura Chico reiterates Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and m

Larimar Therapeutics Inc (NASDAQ: LRMR) shares are trading sharply higher Tuesday after the company

Gainers Powerbridge Technologies Co., Ltd. (NASDAQ: PBTS) shares surged 65.4% to close at $2.10 o